adt plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: systemic review
Published 8 years ago • 168 plays • Length 5:49Download video MP4
Download video MP3
Similar videos
-
1:56
arasens: dialuramide plus adt and docetaxel for metastatic hormone-sensitive prostate cancer
-
5:51
addition of docetaxel to initial hormone therapy improves survival in prostate cancer
-
6:48
docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic prostate cancer
-
17:44
new approaches to metastatic hormone sensitive prostate cancer
-
1:19
role of the addition of docetaxel to adt in mhspc
-
3:45
first effective adjuvant chemotherapy for high-risk, localised prostate cancer
-
55:35
is there still a role for docetaxel in mhspc?
-
1:43
dr. oh on the role of docetaxel in metastatic hormone-sensitive prostate cancer
-
3:27
chaarted: adt docetaxel for prostate cancer
-
0:51
os sensitivity analysis of darolutamide, docetaxel and adt in arasens
-
1:44
arasens: the addition of darolutamide to adt and docetaxel for the treatment of mhspc
-
1:37
dr. oh discusses the use of abiraterone and docetaxel in prostate cancer
-
1:14
arasens: dialuramide plus adt and docetaxel in mhspc stratified by disease risk volume
-
2:12
abiraterone for metastatic, hormone sensitive, prostate cancer
-
14:15
expert insight: metastatic hormone sensitive prostate cancer latest
-
9:48
adt plus tak-700 with adt plus bicalutamide in patients with newly diagnosed mhspc
-
1:55
arches trial overview: adt plus enzalutamide for metastatic hormone-sensitive prostate cancer
-
5:16
exciting advances in systemic therapy for prostate cancer: docetaxel and abiraterone
-
5:59
peace-1 points to benefit of adding abiraterone to adt–docetaxel in de novo mcspc | karim fizazi